A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure how much of the drug gets into the bloodstream and
how long it takes the body to remove it when given to participants with hepatic (liver)
impairment compared to participants with normal hepatic function. Information about any side
effects that may occur will also be collected. This study will last approximately 28 days,
not including screening.